Ontology highlight
ABSTRACT:
SUBMITTER: Lee JS
PROVIDER: S-EPMC3280623 | biostudies-other | 2012
REPOSITORIES: biostudies-other
Lee Janice Soo Fern JS Calmy Alexandra A Andrieux-Meyer Isabelle I Ford Nathan N
HIV/AIDS (Auckland, N.Z.) 20120112
Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good efficacy and safety, with minimal side effects and no specific requirements in terms of laboratory monitoring. In addition, elvitegravir is available as a fixed-dose combination. However, the drug requ ...[more]